Pro-ficiency has unveiled a new approach to educating and supporting U.S. cystic fibrosis (CF) patients and caregivers using its new platform, ProPatient. Pro-ficiency, based in Durham, North Carolina, provides online training technology for clinical trials. It platforms use real-world simulation scenarios to educate clinicians and physicians. ProPatient, which uses videos…
News
Vizient, which calls itself the nation’s “largest member-driven health care performance improvement company,” has awarded a contract for  Alcresta’s Relizorb — a product that helps with the digestion of healthy fats in serious diseases such as cystic fibrosis (CF). The Relizorb (immobized lipase) cartridge contains an enzyme that breaks down fats in tube…
Two months and 13,456 miles after TV and radio host Riki Rachtman committed to a solo motorcycle journey through all 48 contiguous states, the TV and radio host has completed his goal:, to raise funds for Claire’s Place Foundation, a nonprofit working with children and families touched by…
4D Molecular Therapeutics (4DMT) announced it has secured funding to complete studies necessary for its gene therapy candidate for cystic fibrosis (CF), 4D-710, to be tested in people. The therapy is composed of a what 4DMT describes as an advanced and customized adeno-associated virus (AAV) vector, which will carry…
The lunges keep coming for Lunges4Lungs, even as Mallory Smith recovers from the double lung transplant she has received to help extend her life. Friends of Smith started the transplant fundraising campaign, which involves people making donations for each of the leg-muscle exercises known as lunges that they perform. Although…
The U.S. Food and Drug Administration (FDA) granted orphan drug status to a broad spectrum antibiotic called iclaprim, developed by Motif Bio, for the treatment of one of the most common lung infections in patients with cystic fibrosis (CF), Staphylococcus aureus. The FDA’s designation could accelerate the availability of iclaprim for CF patients.
Nitric oxide (NO) inhalation can enhance the antibiotic treatment of Pseudomonas aeruginosa biofilm infections in cystic fibrosis (CF) patients, a small proof-of-concept clinical trial demonstrated. Bacterial infections by P. aeruginosa is a major cause of long-term morbidity and mortality in patients with CF. The bacteria can form biofilms, which are structured, antibiotic-tolerant aggregates…
A nitric oxide therapy that AIT Therapeutics‘ is developing to treat respiratory diseases eradicated a drug-resistant bacteria in one cystic fibrosis patient and reduced it in another, according to a Phase 2 clinical trial. The patients received the treatment under the Food and Drug Administration’s compassionate use program, which allows…
AbbVie is awarding three $25,000 scholarships this year to mark the 25th anniversary of its CF Scholarship Program, and is creating a new Blogger’s Choice Award category. AbbVie selected 40 undergraduate and graduate students living with cystic fibrosis (CF) earlier this year to receive $3,000 scholarships for this…
A new study shows that weight gain during the treatment of acute worsening symptoms in patients with cystic fibrosis (CF), called pulmonary exacerbations, could possibly lengthen the period before symptoms worsen again. These results were published in the European Respiratory Journal Open Research, in an article titled, “…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.